FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567123034> ?p ?o ?g. }

• W2567123034 endingPage "9242" @default.
• W2567123034 startingPage "9230" @default.
• W2567123034 abstract "// Meng Ye 1 , Tao Huang 1 , Ying Ying 3 , Jinyun Li 1 , Ping Yang 1, 2 , Chao Ni 1, 2 , Chongchang Zhou 2 , Si Chen 1 1 The Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315020, People’s Republic of China 2 Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, People’s Republic of China 3 Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, People’s Republic of China Correspondence to: Meng Ye, email: yemeng@nbu.edu.cn Tao Huang, email: huangtao334@163.com Keywords: 14-3-3 σ, promoter methylation, breast cancer, blood, diagnosis, biomarker Received: September 27, 2016      Accepted: December 12, 2016      Published: December 16, 2016 ABSTRACT As a tumor suppressor gene, 14-3-3 σ has been reported to be frequently methylated in breast cancer. However, the clinical effect of 14-3-3 σ promoter methylation remains to be verified. This study was performed to assess the clinicopathological significance and diagnostic value of 14-3-3 σ promoter methylation in breast cancer. 14-3-3 σ promoter methylation was found to be notably higher in breast cancer than in benign lesions and normal breast tissue samples. We did not observe that 14-3-3 σ promoter methylation was linked to the age status, tumor grade, clinic stage, lymph node status, histological subtype, ER status, PR status, HER2 status, or overall survival of patients with breast cancer. The combined sensitivity, specificity, AUC (area under the curve), positive likelihood ratios (PLR), negative likelihood ratios (NLR), diagnostic odds ratio (DOR), and pos t-test probability values (if the pretest probability was 30%) of 14-3-3 σ promoter methylation in blood samples of breast cancer patients vs. healthy subjects were 0.69, 0.99, 0.86, 95, 0.31, 302, and 98%, respectively. Our findings suggest that 14-3-3 σ promoter methylation may be associated with the carcinogenesis of breast cancer and that the use of 14-3-3 σ promoter methylation might represent a useful blood-based biomarker for the clinical diagnosis of breast cancer." @default.
• W2567123034 created "2017-01-06" @default.
• W2567123034 creator A5004967316 @default.
• W2567123034 creator A5021240812 @default.
• W2567123034 creator A5030458072 @default.
• W2567123034 creator A5033070500 @default.
• W2567123034 creator A5048333692 @default.
• W2567123034 creator A5052173587 @default.
• W2567123034 creator A5072391290 @default.
• W2567123034 creator A5076385892 @default.
• W2567123034 date "2016-12-16" @default.
• W2567123034 modified "2023-10-17" @default.
• W2567123034 title "Detection of <i>14-3-3 sigma</i> (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis" @default.
• W2567123034 cites W1549906179 @default.
• W2567123034 cites W164533244 @default.
• W2567123034 cites W1685927984 @default.
• W2567123034 cites W191064394 @default.
• W2567123034 cites W1944821505 @default.
• W2567123034 cites W1965532678 @default.
• W2567123034 cites W1967255508 @default.
• W2567123034 cites W1968945660 @default.
• W2567123034 cites W1974371450 @default.
• W2567123034 cites W1982228885 @default.
• W2567123034 cites W1987554958 @default.
• W2567123034 cites W1994846170 @default.
• W2567123034 cites W2009983545 @default.
• W2567123034 cites W2016655576 @default.
• W2567123034 cites W2032479171 @default.
• W2567123034 cites W2043826252 @default.
• W2567123034 cites W2053777488 @default.
• W2567123034 cites W2060230986 @default.
• W2567123034 cites W2062190843 @default.
• W2567123034 cites W2075777191 @default.
• W2567123034 cites W2076956902 @default.
• W2567123034 cites W2079872885 @default.
• W2567123034 cites W2091642060 @default.
• W2567123034 cites W2094436430 @default.
• W2567123034 cites W2096910745 @default.
• W2567123034 cites W2097997050 @default.
• W2567123034 cites W2098141312 @default.
• W2567123034 cites W2100509624 @default.
• W2567123034 cites W2128745883 @default.
• W2567123034 cites W2130603065 @default.
• W2567123034 cites W2136156766 @default.
• W2567123034 cites W2140787953 @default.
• W2567123034 cites W2161888471 @default.
• W2567123034 cites W230099372 @default.
• W2567123034 cites W2301414084 @default.
• W2567123034 cites W2325267338 @default.
• W2567123034 cites W2332695910 @default.
• W2567123034 cites W2419048055 @default.
• W2567123034 cites W2425387679 @default.
• W2567123034 cites W2433575101 @default.
• W2567123034 cites W2437450654 @default.
• W2567123034 cites W2507626480 @default.
• W2567123034 cites W2514888948 @default.
• W2567123034 cites W2519818420 @default.
• W2567123034 cites W2521481705 @default.
• W2567123034 cites W2917837889 @default.
• W2567123034 cites W1600477018 @default.
• W2567123034 doi "https://doi.org/10.18632/oncotarget.13992" @default.
• W2567123034 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5354727" @default.
• W2567123034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27999208" @default.
• W2567123034 hasPublicationYear "2016" @default.
• W2567123034 type Work @default.
• W2567123034 sameAs 2567123034 @default.
• W2567123034 citedByCount "28" @default.
• W2567123034 countsByYear W25671230342017 @default.
• W2567123034 countsByYear W25671230342018 @default.
• W2567123034 countsByYear W25671230342019 @default.
• W2567123034 countsByYear W25671230342020 @default.
• W2567123034 countsByYear W25671230342021 @default.
• W2567123034 countsByYear W25671230342022 @default.
• W2567123034 countsByYear W25671230342023 @default.
• W2567123034 crossrefType "journal-article" @default.
• W2567123034 hasAuthorship W2567123034A5004967316 @default.
• W2567123034 hasAuthorship W2567123034A5021240812 @default.
• W2567123034 hasAuthorship W2567123034A5030458072 @default.
• W2567123034 hasAuthorship W2567123034A5033070500 @default.
• W2567123034 hasAuthorship W2567123034A5048333692 @default.
• W2567123034 hasAuthorship W2567123034A5052173587 @default.
• W2567123034 hasAuthorship W2567123034A5072391290 @default.
• W2567123034 hasAuthorship W2567123034A5076385892 @default.
• W2567123034 hasBestOaLocation W25671230341 @default.
• W2567123034 hasConcept C104317684 @default.
• W2567123034 hasConcept C121608353 @default.
• W2567123034 hasConcept C126322002 @default.
• W2567123034 hasConcept C143998085 @default.
• W2567123034 hasConcept C150194340 @default.
• W2567123034 hasConcept C190727270 @default.
• W2567123034 hasConcept C2781197716 @default.
• W2567123034 hasConcept C29456083 @default.
• W2567123034 hasConcept C33288867 @default.
• W2567123034 hasConcept C530470458 @default.
• W2567123034 hasConcept C54355233 @default.
• W2567123034 hasConcept C71924100 @default.
• W2567123034 hasConcept C86803240 @default.
• W2567123034 hasConceptScore W2567123034C104317684 @default.

• next